Sponsors (2)
The bill greatly expands interstate telehealth access to psychiatric and controlled‑substance medications and reduces administrative barriers for clinicians, but does so at the cost of increased public‑health risk from diversion/inappropriate prescribing, higher compliance costs that may squeeze small providers, and reduced state/local regulatory control.
People with mental health conditions, patients with opioid use disorder, and rural or underserved patients can obtain FDA‑approved psychiatric drugs and schedule II–V medications via a single telehealth evaluation, improving timely access to care.
Telehealth clinicians (especially psychiatrists) face reduced administrative burden—easier designation of a company's address as principal place of practice and limited new-state licensure when requirements are substantially similar—making interstate telepractice simpler and expanding remote clinician capacity.
Telehealth companies must meet staffing, accreditation, and monitoring standards (e.g., CMO/CCO, accreditation), which could strengthen clinical oversight and patient safety at telehealth providers that comply.
Expanded telehealth prescribing of controlled substances raises the risk of inappropriate prescribing and diversion, potentially harming public health if monitoring and safeguards do not keep pace.
Extensive new staffing, accreditation, monitoring, workforce and compensation mandates will increase operational costs for telehealth providers, likely reducing low‑cost options, disadvantaging small/new providers, and encouraging consolidation.
Civil penalties (up to $25,000) and strict filling rules expose pharmacists and pharmacies to financial risk and litigation, which could deter legitimate clinical judgment and create access delays.
Based on analysis of 5 sections of legislative text.
Expands when controlled substances for mental‑health conditions can be prescribed via telehealth, eases DEA/state registration for telemedicine providers, permits cross‑state telepsychiatry under limits, and preempts conflicting state laws.
Introduced January 9, 2026 by Neal Patrick Dunn · Last progress January 9, 2026
Expands when controlled substances for mental-health conditions may be prescribed following evaluations done by telehealth, clarifies which medicines qualify, and creates exceptions for telehealth organizations and practitioners on DEA/state registration requirements. It also lets psychiatrists licensed and insured in one state provide telepsychiatry to patients in other states (subject to limits), requires malpractice coverage to apply as if care were provided in the psychiatrist’s home state (with possible premium adjustments), and preempts state laws that would block these activities. Several defined terms and thresholds (for example, what counts as an "approved mental health controlled substance," qualifying telehealth entities, and staffing thresholds) set who and what qualifies under the rules.